IP Library Granted Patent US 9,366,683
Granted Patent B2
US 9,366,683 · App. 14/524,031 · Granted Jun 14, 2016

Methods for diagnosis and prognosis of renal injury and renal failure

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,366,683
App. No.
14/524,031
Granted
Jun 14, 2016
Kind
B2
Abstract

The present invention relates to methods and compositions for monitoring subjects suffering from a renal injury. In particular, the invention relates to using assays that detect Beta-2-glycoprotein 1 as a prognostic biomarker in renal injuries.

Claims (8)

1. A method for evaluating renal status in a subject, comprising:

performing an assay method configured to detect Beta-2-glycoprotein 1 by introducing a body fluid sample obtained from the subject into an assay instrument which (i) contacts all or a portion of the body fluid sample with a binding reagent which specifically binds for detection Beta-2-glycoprotein 1 and (ii) generates an assay result indicative of Beta-2-glycoprotein 1 binding to the binding reagent;

correlating the assay result generated by the assay instrument to a likelihood that the renal function of the subject will improve within 72 hours of the time at which the body fluid sample is obtained from the subject by using the assay result to assign the subject to a predetermined subpopulation of individuals having a current acute renal injury and that have a known predisposition to the nonoccurrence of continued acute renal failure within 72 hours.

2. A method according to claim 1 , wherein said correlating step comprises correlating the assay result to a likelihood that the renal function of the subject will improve within 48 hours of the time at which the body fluid sample is obtained.

3. A method according to claim 2 , wherein said correlating step comprises correlating the assay result to a likelihood that the renal function of the subject will improve within 24 hours of the time at which the body fluid sample is obtained.

4. A method according to claim 1 , wherein the subject is in RIFLE stage I or F.

5. A method according to claim 1 , wherein said correlating step comprises correlating the assay result to a likelihood that the renal function of the subject will improve within 48 hours of the time at which the body fluid sample is obtained.

6. A method according to claim 5 , wherein said correlating step comprises correlating the assay result to a likelihood that the renal function of the subject will improve within 24 hours of the time at which the body fluid sample is obtained.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded May 4, 2018
From: CAPITAL ROYALTY PARTNERS II L.P.; CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.; PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
To: ASTUTE MEDICAL, INC.
Reel/Frame 046077/0084 →
SECURITY INTEREST Recorded Jul 7, 2015
From: ASTUTE MEDICAL, INC.
To: CAPITAL ROYALTY PARTNERS II L.P.; CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.; PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
Reel/Frame 036075/0141 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 2, 2014
From: ANDERBERG, JOSEPH; GRAY, JEFF; MCPHERSON, PAUL; NAKAMURA, KEVIN
To: ASTUTE MEDICAL, INC.
Reel/Frame 034313/0956 →